For neoadjuvant treatment of high-risk hormone receptor positive, HER2-negative BC, there are two phase III trials currently ongoing: the KEYNOTE-756 (NCT03725059), in which pembrolizumab is used in both the neoadjuvant and adjuvant phases, and CheckMate 7FL (NCT04109066), in which nivolumab is used in both settings as well. The gene discussed is ERBB2; the disease is breast cancer.